Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Relmada Therapeutics Inc. (RLMD)

40.18   1.19 (3.05%) 09-20 20:23
Open: 39.5 Pre. Close: 38.99
High: 40.18 Low: 38.27
Volume: 154,204 Market Cap: 644M
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in New York City, New York and currently employs 6 full-time employees. The firm is engaged in developing a pipeline of drug candidates to treat chronic pain. Its product candidates include d-Methadone (dextromethadone, REL-1017), LevoCap ER (REL-1015), BuTab (REL-1028) and MepiGel (REL-1021). Its d-Methadone is an N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain. Its REL-1015 is an extended release, abuse deterrent formulation of the opioid analgesic levorphanol, which is pharmacologically differentiated from morphine, oxycodone and other opioids for the management of pain severe enough to require daily, around-the-clock and long-term opioid treatment. REL-1028 represents formulations of oral, modified release buprenorphine being developed for both chronic pain and opioid dependence indications. REL-1021 is a topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 40.228 - 40.383 40.383 - 40.538
Low: 37.872 - 38.054 38.054 - 38.236
Close: 39.877 - 40.165 40.165 - 40.452

Technical analysis

as of: 2020-09-18 4:35:08 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 47.74     One year: 55.76
Support: Support1: 36.45    Support2: 33.72
Resistance: Resistance1: 40.87    Resistance2: 47.74
Pivot: 37.29
Moving Average: MA(5): 39.06     MA(20): 37.08
MA(100): 41.77     MA(250): 36.79
MACD: MACD(12,26): 0.19     Signal(9): -0.31
Stochastic oscillator: %K(14,3): 77.06     %D(3): 70.89
RSI: RSI(14): 58.69
52-week: High: 54.00  Low: 9.60  Change(%): 253.7
Average Vol(K): 3-Month: 14233  10-Days: 8685

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
RLMD has closed below upper band by 0.3%. Bollinger Bands are 19.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 14 Sep 2020
Does Relmada Therapeutics Inc (RLMD) Have What it Takes to be in Your Portfolio? - InvestorsObserver

Mon, 31 Aug 2020
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Relmada Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors - Yahoo Finance

Thu, 27 Aug 2020
Have Insiders Been Buying Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares? - Simply Wall St

Thu, 27 Aug 2020
Do Insiders Own Lots Of Shares In Relmada Therapeutics, Inc. (NASDAQ:RLMD)? - Yahoo Finance

Mon, 13 Jul 2020
Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market® - PRNewswire

Fri, 26 Jun 2020
We're Not Worried About Relmada Therapeutics's (NASDAQ:RLMD) Cash Burn - Yahoo Finance

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability n/a
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers General Specialty & Generic
Shares Out. (M) 16
Shares Float (M) 10
% Held by Insiders 4.31
% Held by Institutions 48.04
Shares Short (K) 1,850
Shares Short P. Month (K) 2,140

Stock Financials

EPS -2.220
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 8.340
Profit Margin
Operating Margin
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -1.931
Qtrly Earnings Growth
Operating Cash Flow (M) -16
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio -18.10
PEG Ratio
Price to Book value 4.82
Price to Sales
Price to Cash Flow -41.45

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.